Investigators discuss the role of SHP2 in cancer and the tumor microenvironment, and the clinical strategies in which SHP2 inhibitors are leveraged as combination agents to improve therapeutic response.
[Cancer Discovery]
Home Newsletters Extracellular Matrix News SHP2: A Pleiotropic Target at the Interface of Cancer and Its Microenvironment
